Vemurafenib is the first BRAF inhibitor that is used to treat advanced malignant melanoma. Early results show that it may prolong life for several months, but the drug is also prohibitively expensive and has several severe adverse effects. The oncology nurse and the pharmacist must educate the patient on the importance of monitoring their skin for new skin cancers. Additionally, these patients need regular monitoring of their liver and renal function.